CT
Cadrenal Therapeutics, Inc.
SEC filingBiotechnology · Ponte Vedra, FL
Amount raised$8.8Msold at filing
Total offering$8.8M
Investors in the raise1count reported to the SEC
FiledJul 15, 2026first sale Jun 30, 2026
Form D does not name the investors. If a news report names them, they appear here.
Named in the filing
Jeffrey S. ColeExecutive Officer
Quang X. PhamExecutive Officer, Director
Lee S. GoldenDirector
Glynn R. WilsonDirector
John R. MurphyDirector
John P. SharpExecutive Officer
James J. FergusonExecutive Officer
Executive officers, directors and promoters as listed on the Form D.